About PackGene

PackGene is a world-leading adeno-associated virus (AAV) vector CRO and CDMO company, providing economical, reliable, and scalable plasmid DNA and AAV viral vector production for early-stage drug discovery, preclinical development and clinical trials for Cell and Gene Therapy (CGT).  The proprietary π-Alpha™ 293 AAV High-yield Platform uses uniquely designed RC plasmid in the triple-plasmid transfection system to increase AAV production by 3 to 8 times in various AAV serotypes. With combining both in-process upstream and downstream QbD optimizations, the total AAV yield can be increased up to 10 times. The single batch of AAV production delivers up to 1E+17vg virus particles which can meet the needs of most clinical-level and commercial levels of AAV production.

PackGene offers 8,000m² state-of-the-art GMP facilities in compliance with the FDA, NMPA, and EMA regulatory requirements with the first 4,000L GMP AAV production capacity in Asia. We have successfully delivered over 10,000 batches of research-grade AAV packaging services for hundreds of big pharma, biotech and research institutions from the United States, Europe, Asia Pacific, and China. We dedicate ourselves to the new serotype AAV vectors development and high-yield AAV production technology to accelerate your gene therapy programs.  PackGene continuously strives to improve the quality, yield, efficacy, and safety of plasmid DNA and AAV vector to make gene therapy affordable for patients.